Aclidinium bromide/formoterol

Drug Profile

Aclidinium bromide/formoterol

Alternative Names: Aclidinium bromide/formoterol fumarate; BrimicaGenuair; Duaklir®; DuaklirGenuair; Formoterol fumarate/aclidinium bromide; KRP-AB1102F; LAS40464

Latest Information Update: 09 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratorios Almirall
  • Developer Allergan; Almirall S.A.; AstraZeneca; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 11 Sep 2017 AstraZeneca plans a phase II trial for Chronic obstructive pulmonary disease in China (NCT03276078)
  • 07 Sep 2017 AstraZeneca announces intention to submit NDA aaplication with the US FDA for Chronic obstructive pulmonary disease in first half of 2018
  • 09 Jun 2017 AstraZeneca completes the phase III AMPLIFY trial in Chronic obstructive pulmonary disease in Germany, Hungary, Bulgaria, Czech Republic, Israel, Poland, Spain, Ukraine, USA, United Kingdom (NCT02796677)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top